# Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

> **NCT04352777** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Locally Advanced Breast Cancer
- Hormone Receptor Positive Tumor

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Fulvestrant
- **DRUG:** Aromatase Inhibitors

## Key facts

- **NCT ID:** NCT04352777
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-14
- **Primary completion:** 2025-06-25
- **Final completion:** 2025-06-25
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04352777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04352777, "Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04352777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*